Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, has been making strides in the healthcare sector with its focus on developing innovative therapeutics for fibrosis-related diseases. These diseases represent a significant unmet medical need, and Chemomab’s efforts are directed towards addressing this gap through cutting-edge research and development.

Headquartered in Tel Aviv, Israel, Chemomab Therapeutics operates on a global scale, leveraging its expertise to advance its pipeline of potential treatments. The company’s primary exchange listing is on the Nasdaq, where it trades under the currency of USD. As of October 9, 2025, the close price of Chemomab’s stock was recorded at $3.28. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of $9.84 on January 6, 2025, and a 52-week low of $2.39 on September 21, 2025.

The market capitalization of Chemomab Therapeutics stands at approximately $15,467,495 USD, reflecting its position and potential within the biotechnology industry. Since its initial public offering (IPO) on February 12, 2019, the company has been committed to its mission of discovering and developing therapies that could significantly impact patients suffering from fibrosis-related conditions.

Chemomab’s strategic focus on fibrosis-related diseases is driven by the high unmet need in this area, where current treatment options are limited. The company’s research endeavors are aimed at identifying novel therapeutic targets and developing treatments that could improve patient outcomes and quality of life.

For more information about Chemomab Therapeutics Ltd., stakeholders and interested parties can visit their official website at www.chemomab.com . The company continues to engage with the global healthcare community, sharing updates on its progress and developments in the field of biotechnology.